

**Amendments to the Specification**

The marked-up version of the amendments below are relative to the "as filed" original specification. Applicants attach as Exhibit A the amendments below relative to the amendment filed October 25, 2004 if the amendments to the specification were entered.

On page 1 of the specification, please replace the title with the following amended title:

**METHODS FOR TREATING HYPERACTIVE ~~GASTRIC~~ GASTROINTESTINAL MOTILITY**

Please replace the paragraph beginning on page 1, line 12 and ending on line 17 with the following amended paragraph:

This invention relates to novel methods for modulating ~~gastric~~ gastrointestinal tissues utilizing compounds which modulate the KCNQ family of potassium channels, particularly compounds which open or agonize the channels. The methods of this invention include the treatment, prevention, inhibition and amelioration of hyperactive ~~gastric~~ gastrointestinal motility, including that associated with colitis, Irritable Bowel Syndrome and Crohn's Disease.

Please replace the paragraph on page 3, beginning at line 11 and ending at line 22 with the following amended paragraph:

This invention comprises methods for treating, preventing, inhibiting, alleviating or controlling hyperactive ~~gastric~~ gastrointestinal motility in a mammal, the methods comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound which acts as an agonist or opener of the KCNQ family of potassium channels, including the KCNQ2, KCNQ3, KCNQ4, and KCNQ5 potassium channels, alone or in combination. A particular embodiment of this invention includes use in the methods described herein of one or more agonists or openers of KCNQ2/3 potassium channels. Another series of methods of this invention comprises use of one or more agonists or openers of KCNQ3/5 potassium channels. Further methods of this invention comprise treatment of the bladder instability conditions

described herein by pharmaceutical administration of one or more agonists or openers of KCNQ4 potassium channels.

Please replace the paragraph on page 3, beginning at line 24 and ending at line 26 with the following amended paragraph:

Specific methods of this invention include the treatment, prevention, inhibition, alleviation or control of hyperactive ~~gastrie~~ gastrointestinal motility associated with colitis, irritable bowel syndrome (IBS) or Crohn's Disease.

Please replace the paragraph on page 11, beginning at line 16 and ending at line 25 with the following amended paragraph:

The methods of this invention are useful for treating, preventing, inhibiting or ameliorating hyperactive ~~gastrie~~ gastrointestinal motility in a mammal, the methods each comprising administering to a mammal in need of such treatment a pharmaceutically effective amount of a KCNQ potassium channel opener, as described above. The conditions which may be treated with the methods of this invention include irritable bowel syndrome, also known as spastic colon, Crohn's Disease and mucous colitis. The methods of this invention may also be used for mammalian gastrointestinal (GI) conditions including diarrhea, chronic diarrhea, acute ~~diarhea~~ diarrhea, abdominal pain associated with diarrhea, postprandial urgency, postprandial accentuation of diarrhea or abdominal pain, or a combination of two or more of these symptoms.

Please replace the paragraph beginning at page 14, line 36 and ending at page 15, line 14 with the following amended paragraph:

As used herein, the terms "pharmaceutically effective amount" or "therapeutically effective amount" mean the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, prevention or amelioration of hyperactive ~~gastrie~~ gastrointestinal motility or the excessive or undesirable urge to defecate, or a decrease in the frequency of incidence of fecal incontinence. When the malady in question warrants, a pharmaceutically or therapeutically effective dose may

**Serial No.: 10/635,081**  
**Confirmation No.: 7223**  
**Art Unit: 1614**

**AM100632D1**

be considered the minimal amount of the compound in question which will alleviate, inhibit or remove the cramping, pressure, pain or feeling of fecal urgency associated with hyperactive ~~gastrie~~ gastrointestinal motility. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

Please cancel the Abstract Of The Disclosure in its entirety, and add the attached new Abstract Of The Disclosure.